Singapore markets close in 3 hours 9 minutes
Straits Times Index
3,308.79 +8.79 (+0.27%) Nikkei
38,601.81 -31.21 (-0.08%) Hang Seng
18,076.45 -258.87 (-1.41%) FTSE 100
8,272.46 +67.35 (+0.82%) Bitcoin USD
64,553.69 -864.55 (-1.32%) CMC Crypto 200
1,353.43 -29.23 (-2.11%)
PCVX Jan 2025 115.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 09:30AM EDT. Market open.
| Previous close | 7.70 |
| Open | N/A |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 115.00 |
| Expiry date | 2025-01-17 |
| Day's range | 7.70 - 7.70 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Simply Wall St.We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- GuruFocus.com
Vaxcyte Inc (PCVX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Overview
Consistent with Analyst Projections Amidst Strategic Advancements
GlobeNewswireVaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 Infant Phase 2 Study Enrollment Completed; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 -- -- $1.9 Billion in Cash, Cash Equivalen
© 2024 Yahoo. All rights reserved.